Alkem Laboratories Share News - Latest Updates, Live News & More

Latest news about Alkem Laboratories

Alkem Laboratories Faces Rs. 54.94 Lakh GST Demand Order from Uttarakhand Authorities 14 hours ago Yesterday

Alkem Laboratories received a GST demand order of Rs. 54.94 lakh from the Assistant Commissioner, Central Goods Service Tax Division in Dehradun. The order covers FY 2018-2019 to 2022-2023, alleging excess Input Tax Credit availment. The amount includes a GST demand of Rs. 27.14 lakh and a penalty of Rs. 27.79 lakh. Alkem disagrees with the order and plans to contest it. The company states there's no material impact on its operations and has disclosed this information in compliance with SEBI regulations.

Alkem Laboratories' Sikkim Facility Clears Armenian GMP Inspection Nov 22, 2025

Alkem Laboratories Enters Probiotic Market with Launch of DSS in India Nov 20, 2025

Alkem Laboratories Reports Strong Q2 Results with 17.2% Revenue Growth Nov 19, 2025

Alkem Laboratories Faces Rs 3.61 Crore GST Demand, Plans to Contest Nov 18, 2025

More news about Alkem Laboratories

13Nov 25

Alkem Laboratories Reports Strong Growth for Q2 and H1 FY26

Alkem Laboratories announced robust financial results for Q2 and H1 FY26. Q2 revenue increased by 17.2% YoY to ₹40,010.00 million, with EBITDA growing 22.3% YoY. Net profit rose to ₹1,279.80 million. Domestic revenue grew 12.4% YoY, while international sales surged 29.5%. The company became the top player in the Indian Pharmaceutical Market's Acute segment. Alkem's US sales grew by 28.0% YoY, contributing 19.3% to total sales. The company continues to strengthen its product pipeline with new ANDA filings and approvals.

10Nov 25

Alkem Labs Successfully Concludes EU GMP Inspection at Baddi Facility

Alkem Laboratories successfully completed a European Union Good Manufacturing Practice (EU GMP) inspection at its Baddi, India facility. The inspection, conducted by the German Health Authority from November 4-10, 2025, concluded without any critical or major observations. This outcome validates Alkem's compliance with EU quality standards and potentially strengthens its position in the European pharmaceutical market.

03Nov 25

Alkem Labs and IIT Bombay Join Forces for Cutting-Edge Research in Immuno-Therapeutics

Alkem Laboratories and IIT Bombay are collaborating to establish the Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines. Alkem Foundation will fund 20-25% of its CSR obligations over seven years for this project. The centre will focus on immuno-therapeutics, regenerative medicines, gene editing, and biomaterials, aiming to bridge gaps in infrastructure, talent, and translational capability. This partnership marks India's first industry-academia collaboration through CSR for research in these specialized areas.

16Oct 25

Alkem Laboratories Sees Rs. 56.15 Crore Block Trade on NSE

A significant block trade of approximately 100,805 shares of Alkem Laboratories occurred on the National Stock Exchange (NSE). The transaction was valued at Rs. 56.15 crores, with shares priced at Rs. 5,570.00 each. This substantial trade indicates notable institutional interest in the Indian pharmaceutical company and may provide insights into investor sentiment towards Alkem Laboratories and the pharmaceutical sector.

01Oct 25

Alkem Laboratories Faces Rs 3.37 Crore GST Demand, Plans Legal Challenge

Alkem Laboratories received an appeal order from the Commissioner of Customs & Central Tax Appeals-II Commissionerate in Hyderabad, confirming a GST demand of Rs 3.37 crore plus a penalty of Rs 33.93 lakh for the period 2020-2021 to 2021-2022. The order alleges excess availment of Input Tax Credit under IGST, CGST, and SGST Acts. Alkem disagrees with the demand and plans to contest it through legal actions, asserting it has adequate grounds to defend its position. The company states this order does not materially impact its financial or operational activities.

26Sept 25

Alkem Labs to Transfer Trade Generics Business, Reports Strong Q1 Results Amid GST Challenges

Alkem Laboratories has entered a business transfer agreement with its subsidiary, Alkem Wellness Limited, to transfer its trade generics business effective October 1, 2025. The company reported robust Q1 FY2026 results with revenue of ₹3,371 crore (11% YoY growth) and net profit of ₹668 crore (21.45% YoY growth). However, Alkem faces a GST order demanding ₹35.11 crore plus a ₹3.50 crore penalty, which the company plans to contest. Despite strong results, Alkem's shares closed 1.72% lower at ₹5,413.50.

26Sept 25

Alkem Lab to Transfer Trade Generics Business to Alkem Wellness

Alkem Laboratories Limited has announced the transfer of its Trade Generics Business to its wholly-owned subsidiary, Alkem Wellness Limited, effective October 1, 2025. The company has entered into a Business Transfer Agreement for this restructuring move, which will be executed on a slump sale basis. This decision, initially communicated on December 10, 2024, aims to streamline operations and potentially enhance operational efficiency. The disclosure was made in compliance with SEBI regulations.

22Sept 25

Alkem Laboratories Faces GST Demand and Launches Breakthrough Cancer Treatment

Alkem Laboratories received a GST demand of Rs. 35.11 crore with a Rs. 3.51 crore penalty, which they plan to contest. The company also launched Pertuza, a pertuzumab biosimilar for HER2-positive breast cancer in India, aiming to improve accessibility and affordability of cancer treatments. Alkem reported strong quarterly results with revenue of ₹3,371.00 crore, up 11% year-on-year, and net profit of ₹668.00 crore, up 21.50%.

06Sept 25

Alkem Laboratories Announces Rs 4 Final Dividend, Reappoints Managing Director

Alkem Laboratories has recommended a final dividend of Rs 4.00 per equity share. The company's 48th AGM is scheduled for August 25, 2022, with August 10, 2022, set as the record date for dividend eligibility. The Board has approved the reappointment of Sandeep Singh as Managing Director for a five-year term from October 17, 2022, to October 16, 2027, subject to shareholder approval. Auditors have expressed an unmodified opinion on the company's financial results.

05Sept 25

Alkem Laboratories Sets Board Meeting for Q3 Results and Interim Dividend Discussion

Alkem Laboratories has scheduled a Board of Directors meeting for February 7, 2025, to review Q3 and nine-month financial results ending December 31, 2024, and consider an interim dividend for FY 2024-2025. The tentative record date for the potential dividend is set for February 14, 2025, subject to board approval.

19Aug 25

Alkem Laboratories Reports Robust Q1 Results with 11.2% Revenue Growth and Strategic Expansion

Alkem Laboratories reported robust Q1 financial results with total revenue growing 11.2% year-over-year to INR 33,711.00 million. India sales grew by 12% to INR 22,656.00 million, while the U.S. business expanded by 8.8% to INR 6,982.00 million. EBITDA rose by 21.4% to INR 7,391.00 million, with a margin of 21.9%. Net profit increased by 21.8% to INR 6,643.00 million. The company outperformed the Indian Pharmaceutical Market growth in key therapy areas and maintained its full-year guidance with potential to exceed targets.

12Aug 25

Alkem Laboratories Reports Robust Q1 Performance with 11.2% Revenue Growth

Alkem Laboratories announced impressive Q1 financial results, with total revenue reaching ₹33,711.00 million, an 11.2% year-over-year increase. Net profit grew by 21.8% to ₹6,643.00 million, while EBITDA margin improved to 21.9%. The company's domestic sales rose by 12.0% to ₹22,650.00 million, outperforming the Indian Pharmaceutical Market. International sales, including US and non-US markets, also showed positive growth. Alkem demonstrated strong performance across multiple therapy areas and continued its commitment to R&D with new product launches and ANDA approvals.

04Jun 25

Alkem Laboratories: Promoter Offloads 1.4% Stake in Block Deal

Jayanti Sinha, a promoter of Alkem Laboratories, executed a block deal to sell a 1.4% equity stake in the company. The transaction was valued at approximately ₹825.00 crore, with a floor price set at ₹4,850.00 per share. Following the news, Alkem's stock showed a marginal decline of 0.20%, trading at ₹4,985.00.

03Jun 25

Alkem Lab Shares in Focus: Ms. Jayanti Sinha Offloads 1.42% Stake in ₹825 Crore Block Deal

Ms. Jayanti Sinha, a major stakeholder in Alkem Laboratories Ltd., has sold a 1.42% stake in the company through a block deal. The transaction was executed at a floor price of ₹4,850.00 per share, totaling approximately ₹825.00 crore. This significant stake sale by a key shareholder may influence the stock's trading pattern in the near term.

03Jun 25

Alkem Laboratories Promoter to Offload ₹825 Crore Stake in Block Deal

Jayanti Sinha, a promoter group member of Alkem Laboratories, plans to sell a 1.42% stake through a block deal. The floor price is set at ₹4,850.00 per share, a 3.00% discount to the current market price. The transaction, valued at approximately ₹825.00 crore, is scheduled for tomorrow and may impact the company's stock price and ownership structure.

30May 25

Alkem Labs Unveils Ambitious Growth Strategy, Targets Rs. 450-500 Crore from CDMO Business

Alkem Laboratories Ltd has announced strategic plans for growth, focusing on expanding its CDMO business with a target of Rs. 450-500 crore sales in three years. The company projects 1.50% to 2.00% volume growth for the current year, plans to launch 5-6 new products, and expects an EBITDA margin of ~19.50%. Revenue growth is forecasted at 7.00% - 8.00% for the coming year, with potential for slightly higher growth.

30May 25

Alkem Labs Q4 Results Miss Estimates, Jefferies Lowers Price Target

Alkem Laboratories reported Q4 results below market expectations. Revenue grew 7% YoY to Rs 3,104.00 crore, but EBITDA and PAT fell short. EBITDA was 8% below estimates at Rs 393.00 crore, with margins declining 125 basis points to 12.40%. PAT decreased 9% YoY to Rs 308.00 crore. Jefferies maintained an 'underperform' rating and lowered the price target to Rs 4,460.00, citing execution risks in new growth initiatives.

29May 25

Alkem Laboratories Q4 Profit Up 4% YoY, Misses Estimates; Declares ₹8 Dividend

Alkem Laboratories' Q4 results show a 4.26% year-on-year increase in net profit to ₹306.00 crore, falling short of analyst estimates. Revenue grew 7.1% to ₹3,144.00 crore, while EBITDA decreased 2.6% to ₹391.50 crore. The company's India business grew by 6.5%, and international sales rose by 7.2%. Despite mixed results, Alkem announced a dividend of ₹8.00 per share.

15May 25

Alkem Laboratories' US Subsidiary Hit by Cyber Fraud, Financial Loss Under Investigation

Alkem Laboratories' US subsidiary, Enzene Biosciences, has experienced a cyber security breach resulting in unauthorized fund transfers. The company has engaged external agencies for investigation, filed complaints with authorities, and disclosed the incident to stock exchanges. The total amount affected is under investigation, and the full impact on operations is yet to be determined.

28Mar 25

Alkem Laboratories Finalizes Share Purchase Agreement to Acquire Adroit Biomed

Alkem Laboratories Limited has executed a share purchase agreement on March 28, 2025, to acquire a 100% stake in Adroit Biomed Limited. This follows a binding term sheet signed on February 7, 2025. The acquisition is part of Alkem's expansion strategy, aiming to strengthen its market position and expand its product portfolio. The company has informed stock exchanges of this development in compliance with SEBI regulations.

17Mar 25

Alkem Laboratories' Bioequivalence Center Clears FDA Inspection Without Observations

Alkem Laboratories Limited's Bioequivalence Center in Taloja, Maharashtra, successfully completed a U.S. FDA inspection without any Form 483 observations. This outcome demonstrates the facility's compliance with FDA regulations and good clinical practices, potentially boosting investor confidence and facilitating future drug approvals. The clean inspection reinforces Alkem's commitment to maintaining high-quality standards in its R&D processes and strengthens its position in the pharmaceutical industry.

13Mar 25

Alkem Laboratories' US FDA Inspection Concludes Successfully Without Form 483

Alkem Laboratories' bioequivalence center in Taloja, Maharashtra, successfully completed a US FDA Bioresearch Monitoring inspection from March 10-13, 2025, with no Form 483 issued. This outcome indicates compliance with FDA standards and good clinical practices, potentially facilitating smoother drug approvals in the US market and boosting investor confidence.

12Mar 25

Alkem Labs Expands Diabetes Portfolio with Generic Empagliflozin Launch in India

Alkem Laboratories has introduced generic versions of Empagliflozin and its combinations under the brand name 'Empanorm' in India. This launch expands Alkem's diabetes treatment portfolio, offering potentially more affordable options for type 2 diabetes patients. The move aims to strengthen Alkem's position in the competitive diabetes medication market and address the growing diabetes concern in India.

24Feb 25

Alkem Laboratories Promoters Offload ₹300 Crore Worth of Shares in Block Deal

Promoters of Alkem Laboratories sold 641,000 shares (0.54% equity) at ₹4,680 per share through the Samprada & Nanhamati Singh Family Trust, totaling ₹300.3 crore. SBI Mutual Fund was identified as the buyer. Following the deal, Alkem's stock closed at ₹4,600.05, down 2.54%.

21Feb 25

SBI Mutual Fund Boosts Stake in Alkem Laboratories Through Block Deal

SBI Mutual Fund has increased its stake in Alkem Laboratories by 0.54% through a block deal. The fund acquired 6.41 lakh shares at Rs 4,680 per share, totaling Rs 300.32 crore. This transaction brings SBI Mutual Fund's total holding in Alkem to 2.7%. The shares were sold by Samprada & Nanhamati Singh Family Trust, related to Alkem's promoters.